Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

Summary of Recent Updates in MDS

Vanderbilt University Medical Center (VUMC)

S. Ball

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…

UChicago Medicine 12th International Clinical Cancer Genomics Conference

L. Banaszak

Making Sense of the New Classification Systems for MDS in 2024

Moffitt Cancer Center

R. Komrokji

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

Rush University Medical Center

E. Bhaimia

Using Transplant in Patients With p53 Mutant MDS or AML

Moffitt Cancer Center

H. Elmariah

The Truth About Current Consensus Statements on Hematopoietic Cell T…

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

R. Gale

Chronic GvHD: Main Complications After ASCT

Steven Pavletic

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Experts Discuss the Latest Data in Myeloid Diseases

Moffitt Cancer Center

A. Kuykendall, R. Komrokji, O. Chan, D. Sallman

ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based GvHD Pr…

2024 ASCO® Annual Meeting Insights Hub

M. Al Malki

Allo-HSCT Conditioning Regimens: Current Status and Future Directions

Rush University Medical Center

C. Brunstein

Bone Marrow Failure: The Importance of Mutational Testing

Rush University Medical Center

J. Shammo

ASCO® 2023 Insights: "Myeloid for Measure - New Therapeutics in MDS …

Insights from 2023 ASCO® Annual Meeting

A. Patel

Differentiation of CHIP, ICUS, CCUS, MDS, and VEXAS Syndrome

MyCancerHaven

R. Vij, S. Abedin